Placido Maria Mazzone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Placido Maria Mazzone has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Davide Capodanno
University of Catania, Italy
8 shared publications - Daniele Giacoppo
Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
6 shared publications - Davide Landolina
Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico “G. Rodolico–San Marco,” University of Catania, Italy
4 shared publications - Maria Sara Mauro
Azienda Ospedaliero‐Universitaria Policlinico “G. Rodolico‐San Marco”, University of Catania
4 shared publications - Nicola Ammirabile
Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco, University of Catania, Italy (N.A., D.G., P.M.M., D.C.).
4 shared publications - Simone Finocchiaro
Azienda Ospedaliero‐Universitaria Policlinico “G. Rodolico‐San Marco”, University of Catania
4 shared publications
Latest Publications
- 18 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Glucagon-like peptide-1–based therapies in cardiovascular disease: evidence, mechanisms, and emerging clinical applications
Glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed as glucose-lowering therapies for type 2 diabetes mellitus but have progressively emerged as cardiometabolic agents with clinically relevant cardiovascular effects. Large cardiovascular outcome trials have demonstrated reductions in major adverse cardiovascular events in patients with type 2 diabetes and elevated cardiovascular risk, benefits that extend beyond glycemic control. In parallel, the development of dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists has further expanded incretin-based therapy by achieving more potent metabolic effects, raising interest in their potential cardiovascular implications. More recently, pharmacologic treatment of obesity with GLP-1–based therapies has been shown to reduce cardiovascular events in patients without diabetes, while emerging evidence supports a role for these agents in selected populations with heart failure with preserved ejection fraction. These effects appear to reflect integrated metabolic, inflammatory, vascular, and haemodynamic mechanisms. This review summarizes current evidence on the cardiovascular effects of GLP-1 receptor agonists and dual GIP–GLP-1 receptor agonists, discusses safety considerations, and highlights future directions for their clinical application across the cardiometabolic continuum.
- 18 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Glucagon-like peptide-1–based therapies in cardiovascular disease: evidence, mechanisms, and emerging clinical applications
Glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed as glucose-lowering therapies for type 2 diabetes mellitus but have progressively emerged as cardiometabolic agents with clinically relevant cardiovascular effects. Large cardiovascular outcome trials have demonstrated reductions in major adverse cardiovascular events in patients with type 2 diabetes and elevated cardiovascular risk, benefits that extend beyond glycemic control. In parallel, the development of dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists has further expanded incretin-based therapy by achieving more potent metabolic effects, raising interest in their potential cardiovascular implications. More recently, pharmacologic treatment of obesity with GLP-1–based therapies has been shown to reduce cardiovascular events in patients without diabetes, while emerging evidence supports a role for these agents in selected populations with heart failure with preserved ejection fraction. These effects appear to reflect integrated metabolic, inflammatory, vascular, and haemodynamic mechanisms. This review summarizes current evidence on the cardiovascular effects of GLP-1 receptor agonists and dual GIP–GLP-1 receptor agonists, discusses safety considerations, and highlights future directions for their clinical application across the cardiometabolic continuum.
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (6) , e016554
Direct Oral Anticoagulant Monotherapy Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: A Meta-Analysis of Randomized Trials
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (6) , e016554
Open AccessDirect Oral Anticoagulant Monotherapy Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: A Meta-Analysis of Randomized Trials
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e041843
From Caging to Uncaging With Bioadaptors: A Novel Paradigm in Coronary Revascularization
The evolution of percutaneous coronary intervention has improved the outcomes of patients with coronary artery disease, but conventional drug‐eluting stents remain limited by late adverse events, reduced vessel compliance, and the inability to restore physiological function. The DynamX coronary bioadaptor aims to address these issues by combining the mechanical performance of drug‐eluting stents with a bioadaptive mechanism that restores natural vessel motion. The device features a cobalt–chromium scaffold connected by bioresorbable polymer elements that degrade 6 months after implantation. This process unlocks helical strands, enabling vessel pulsatility, compliance, and adaptive remodeling while maintaining lumen integrity. Preclinical studies demonstrated reduced vessel stress and restored physiological rotational motion. In the DYNAMIX (12‐Month Clinical and Imaging Outcomes of the Uncaging Coronary DynamX Bioadaptor System) study, patients exhibited increased vessel area without lumen loss, optimal strut apposition, and complete neointimal coverage at 12 months. The small BIOADAPTOR‐RCT (Randomized Controlled Trial of Sirolimus‐Eluting Bioadaptor Versus Zotarolimus‐Eluting Drug‐Eluting Stent) showed noninferiority to drug‐eluting stents with superior late lumen preservation and reduced neointimal hyperplasia. The larger INFINITY‐SWEDEHEART (Percutaneous Coronary Intervention With a Bioadaptor Compared to a Contemporary Drug‐Eluting Stent) trial confirmed low target‐lesion failure rates and a plateauing of adverse events after 6 months, highlighting the benefits of vessel motion restoration. The DynamX coronary bioadaptor may represent a significant advancement in percutaneous coronary intervention by providing early mechanical support and restoring vessel function. Further studies on complex anatomy and long‐term outcomes are needed to further define its role in interventional cardiology.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e041843
Open AccessFrom Caging to Uncaging With Bioadaptors: A Novel Paradigm in Coronary Revascularization
The evolution of percutaneous coronary intervention has improved the outcomes of patients with coronary artery disease, but conventional drug‐eluting stents remain limited by late adverse events, reduced vessel compliance, and the inability to restore physiological function. The DynamX coronary bioadaptor aims to address these issues by combining the mechanical performance of drug‐eluting stents with a bioadaptive mechanism that restores natural vessel motion. The device features a cobalt–chromium scaffold connected by bioresorbable polymer elements that degrade 6 months after implantation. This process unlocks helical strands, enabling vessel pulsatility, compliance, and adaptive remodeling while maintaining lumen integrity. Preclinical studies demonstrated reduced vessel stress and restored physiological rotational motion. In the DYNAMIX (12‐Month Clinical and Imaging Outcomes of the Uncaging Coronary DynamX Bioadaptor System) study, patients exhibited increased vessel area without lumen loss, optimal strut apposition, and complete neointimal coverage at 12 months. The small BIOADAPTOR‐RCT (Randomized Controlled Trial of Sirolimus‐Eluting Bioadaptor Versus Zotarolimus‐Eluting Drug‐Eluting Stent) showed noninferiority to drug‐eluting stents with superior late lumen preservation and reduced neointimal hyperplasia. The larger INFINITY‐SWEDEHEART (Percutaneous Coronary Intervention With a Bioadaptor Compared to a Contemporary Drug‐Eluting Stent) trial confirmed low target‐lesion failure rates and a plateauing of adverse events after 6 months, highlighting the benefits of vessel motion restoration. The DynamX coronary bioadaptor may represent a significant advancement in percutaneous coronary intervention by providing early mechanical support and restoring vessel function. Further studies on complex anatomy and long‐term outcomes are needed to further define its role in interventional cardiology.
- Open Access
- 19 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (10) , ytaf464
Successful mitral-transcatheter edge to edge repair in a young patient with severe primary mitral regurgitation unsuitable for surgery: a case report
Background: Mitral transcatheter edge-to-edge repair (M-TEER) is commonly performed in elderly patients with severe mitral regurgitation (MR) who are deemed high-risk for surgery. However, its application in younger patients remains limited. Case summary: We present the case of a 45-year-old male with a history of mitral valve prolapse, who developed severe MR due to chordal rupture. Surgical mitral valve repair was not considered feasible, and the patient successfully underwent M-TEER with implantation of two MitraClips XTW (Abbott Medical, USA), resulting in mild residual regurgitation and a mean mitral valve gradient of 5 mmHg. Discussion: This case highlights the potential role of M-TEER in selected young patients, expanding its indications beyond traditional cohorts.
- 19 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (10) , ytaf464
Open AccessSuccessful mitral-transcatheter edge to edge repair in a young patient with severe primary mitral regurgitation unsuitable for surgery: a case report
Background: Mitral transcatheter edge-to-edge repair (M-TEER) is commonly performed in elderly patients with severe mitral regurgitation (MR) who are deemed high-risk for surgery. However, its application in younger patients remains limited. Case summary: We present the case of a 45-year-old male with a history of mitral valve prolapse, who developed severe MR due to chordal rupture. Surgical mitral valve repair was not considered feasible, and the patient successfully underwent M-TEER with implantation of two MitraClips XTW (Abbott Medical, USA), resulting in mild residual regurgitation and a mean mitral valve gradient of 5 mmHg. Discussion: This case highlights the potential role of M-TEER in selected young patients, expanding its indications beyond traditional cohorts.
- Top Cited Papers
- 11 February 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (6) , 400-415
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proinflammatory and prothrombotic mechanisms contributing to its atherogenicity. On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL (low-density lipoprotein). Lp(a) can enter the vessel wall, leading to the accumulation of oxidized phospholipids in the arterial intima, which are crucial for initiating plaque inflammation and triggering vascular disease progression. In addition, Lp(a) may cause atherothrombosis through interactions between apoA (apolipoprotein A) and the platelet PAR-1 (protease-activated receptor 1) receptor, as well as competitive inhibition of plasminogen. Because Lp(a) is mostly determined on genetic bases, a 1-time assessment in a lifetime can suffice to identify patients with elevated levels. Mendelian randomization studies and post hoc analyses of randomized trials of LDL cholesterol–lowering drugs showed a causal link between Lp(a) concentrations and cardiovascular outcomes, with therapeutic reduction of Lp(a) expected to contribute to estimated cardiovascular risk mitigation. Many Lp(a)-lowering drugs, including monoclonal antibodies, small interfering ribonucleic acids, antisense oligonucleotides, small molecules, and gene editing compounds, are at different stages of clinical investigation and show promise for clinical use. In particular, increased Lp(a) testing and treatment are expected to have a substantial impact at the population level, enabling the identification of high-risk individuals and the subsequent prevention of a large number of cardiovascular events. Ongoing phase 3 trials will further elucidate the cardiovascular benefits of Lp(a) reduction over the long term, offering potential avenues for targeted interventions and improved cardiovascular outcomes.
- 11 February 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (6) , 400-415
Top Cited PapersLipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proinflammatory and prothrombotic mechanisms contributing to its atherogenicity. On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL (low-density lipoprotein). Lp(a) can enter the vessel wall, leading to the accumulation of oxidized phospholipids in the arterial intima, which are crucial for initiating plaque inflammation and triggering vascular disease progression. In addition, Lp(a) may cause atherothrombosis through interactions between apoA (apolipoprotein A) and the platelet PAR-1 (protease-activated receptor 1) receptor, as well as competitive inhibition of plasminogen. Because Lp(a) is mostly determined on genetic bases, a 1-time assessment in a lifetime can suffice to identify patients with elevated levels. Mendelian randomization studies and post hoc analyses of randomized trials of LDL cholesterol–lowering drugs showed a causal link between Lp(a) concentrations and cardiovascular outcomes, with therapeutic reduction of Lp(a) expected to contribute to estimated cardiovascular risk mitigation. Many Lp(a)-lowering drugs, including monoclonal antibodies, small interfering ribonucleic acids, antisense oligonucleotides, small molecules, and gene editing compounds, are at different stages of clinical investigation and show promise for clinical use. In particular, increased Lp(a) testing and treatment are expected to have a substantial impact at the population level, enabling the identification of high-risk individuals and the subsequent prevention of a large number of cardiovascular events. Ongoing phase 3 trials will further elucidate the cardiovascular benefits of Lp(a) reduction over the long term, offering potential avenues for targeted interventions and improved cardiovascular outcomes.
- 24 September 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (13) , e271-e272
Response by Giacoppo et al to Letter Regarding Article “Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis”
- 24 September 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (13) , e271-e272
Response by Giacoppo et al to Letter Regarding Article “Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis”
- Open Access
- 19 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2377
Current Management of In-Stent Restenosis
In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available strategies, influenced by a complex interplay between clinical and lesion-specific conditions. Given the multiple mechanisms contributing to the development of ISR, proper identification of the underlying substrate, especially by using intravascular imaging, becomes pivotal as it can indicate distinct therapeutic requirements. Among standalone treatments, drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation have been the most effective. The main advantage of a DCB-based approach is the avoidance of an additional metallic layer, which may otherwise enhance neointimal hyperplasia, provide the substratum for developing neoatherosclerosis, and expose the patient to a persistently higher risk of coronary ischemic events. On the other hand, target vessel scaffolding by DES implantation confers relevant mechanical advantages over DCB angioplasty, generally resulting in larger luminal gain, while drug elution from the stent surface ensures the inhibition of neointimal hyperplasia. Nevertheless, repeat stenting with DES also implies an additional permanent metallic layer that may reiterate and promote the mechanisms leading to ISR. Against this background, the selection of either DCB or DES on a patient- and lesion-specific basis as well as the implementation of adjuvant treatments, including cutting/scoring balloons, intravascular lithotripsy, and rotational atherectomy, hold the potential to improve the effectiveness of ISR treatment over time. In this review, we comprehensively assessed the available evidence from randomized trials to define contemporary interventional treatment of ISR and provide insights for future directions.
- 19 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2377
Open AccessCurrent Management of In-Stent Restenosis
In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available strategies, influenced by a complex interplay between clinical and lesion-specific conditions. Given the multiple mechanisms contributing to the development of ISR, proper identification of the underlying substrate, especially by using intravascular imaging, becomes pivotal as it can indicate distinct therapeutic requirements. Among standalone treatments, drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation have been the most effective. The main advantage of a DCB-based approach is the avoidance of an additional metallic layer, which may otherwise enhance neointimal hyperplasia, provide the substratum for developing neoatherosclerosis, and expose the patient to a persistently higher risk of coronary ischemic events. On the other hand, target vessel scaffolding by DES implantation confers relevant mechanical advantages over DCB angioplasty, generally resulting in larger luminal gain, while drug elution from the stent surface ensures the inhibition of neointimal hyperplasia. Nevertheless, repeat stenting with DES also implies an additional permanent metallic layer that may reiterate and promote the mechanisms leading to ISR. Against this background, the selection of either DCB or DES on a patient- and lesion-specific basis as well as the implementation of adjuvant treatments, including cutting/scoring balloons, intravascular lithotripsy, and rotational atherectomy, hold the potential to improve the effectiveness of ISR treatment over time. In this review, we comprehensively assessed the available evidence from randomized trials to define contemporary interventional treatment of ISR and provide insights for future directions.
- Top Cited PapersOpen Access
- 2 April 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (14) , 1065-1086
Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis
BACKGROUND: Results from multiple randomized clinical trials comparing outcomes after intravascular ultrasound (IVUS)– and optical coherence tomography (OCT)–guided percutaneous coronary intervention (PCI) with invasive coronary angiography (ICA)–guided PCI as well as a pivotal trial comparing the 2 intravascular imaging (IVI) techniques have provided mixed results. METHODS: Major electronic databases were searched to identify eligible trials evaluating at least 2 PCI guidance strategies among ICA, IVUS, and OCT. The 2 coprimary outcomes were target lesion revascularization and myocardial infarction. The secondary outcomes included ischemia-driven target lesion revascularization, target vessel myocardial infarction, death, cardiac death, target vessel revascularization, stent thrombosis, and major adverse cardiac events. Frequentist random-effects network meta-analyses were conducted. The results were replicated by Bayesian random-effects models. Pairwise meta-analyses of the direct components, multiple sensitivity analyses, and pairwise meta-analyses IVI versus ICA were supplemented. RESULTS: The results from 24 randomized trials (15 489 patients: IVUS versus ICA, 46.4%, 7189 patients; OCT versus ICA, 32.1%, 4976 patients; OCT versus IVUS, 21.4%, 3324 patients) were included in the network meta-analyses. IVUS was associated with reduced target lesion revascularization compared with ICA (odds ratio [OR], 0.69 [95% CI, 0.54–0.87]), whereas no significant differences were observed between OCT and ICA (OR, 0.83 [95% CI, 0.63–1.09]) and OCT and IVUS (OR, 1.21 [95% CI, 0.88–1.66]). Myocardial infarction did not significantly differ between guidance strategies (IVUS versus ICA: OR, 0.91 [95% CI, 0.70–1.19]; OCT versus ICA: OR, 0.87 [95% CI, 0.68–1.11]; OCT versus IVUS: OR, 0.96 [95% CI, 0.69–1.33]). These results were consistent with the secondary outcomes of ischemia-driven target lesion revascularization, target vessel myocardial infarction, and target vessel revascularization, and sensitivity analyses generally did not reveal inconsistency. OCT was associated with a significant reduction of stent thrombosis compared with ICA (OR, 0.49 [95% CI, 0.26–0.92]) but only in the frequentist analysis. Similarly, the results in terms of survival between IVUS or OCT and ICA were uncertain across analyses. A total of 25 randomized trials (17 128 patients) were included in the pairwise meta-analyses IVI versus ICA where IVI guidance was associated with reduced target lesion revascularization, cardiac death, and stent thrombosis. CONCLUSIONS: IVI-guided PCI was associated with a reduction in ischemia-driven target lesion revascularization compared with ICA-guided PCI, with the difference most evident for IVUS. In contrast, no significant differences in myocardial infarction were observed between guidance strategies.
- 2 April 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (14) , 1065-1086
Top Cited PapersOpen AccessCoronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis
BACKGROUND: Results from multiple randomized clinical trials comparing outcomes after intravascular ultrasound (IVUS)– and optical coherence tomography (OCT)–guided percutaneous coronary intervention (PCI) with invasive coronary angiography (ICA)–guided PCI as well as a pivotal trial comparing the 2 intravascular imaging (IVI) techniques have provided mixed results. METHODS: Major electronic databases were searched to identify eligible trials evaluating at least 2 PCI guidance strategies among ICA, IVUS, and OCT. The 2 coprimary outcomes were target lesion revascularization and myocardial infarction. The secondary outcomes included ischemia-driven target lesion revascularization, target vessel myocardial infarction, death, cardiac death, target vessel revascularization, stent thrombosis, and major adverse cardiac events. Frequentist random-effects network meta-analyses were conducted. The results were replicated by Bayesian random-effects models. Pairwise meta-analyses of the direct components, multiple sensitivity analyses, and pairwise meta-analyses IVI versus ICA were supplemented. RESULTS: The results from 24 randomized trials (15 489 patients: IVUS versus ICA, 46.4%, 7189 patients; OCT versus ICA, 32.1%, 4976 patients; OCT versus IVUS, 21.4%, 3324 patients) were included in the network meta-analyses. IVUS was associated with reduced target lesion revascularization compared with ICA (odds ratio [OR], 0.69 [95% CI, 0.54–0.87]), whereas no significant differences were observed between OCT and ICA (OR, 0.83 [95% CI, 0.63–1.09]) and OCT and IVUS (OR, 1.21 [95% CI, 0.88–1.66]). Myocardial infarction did not significantly differ between guidance strategies (IVUS versus ICA: OR, 0.91 [95% CI, 0.70–1.19]; OCT versus ICA: OR, 0.87 [95% CI, 0.68–1.11]; OCT versus IVUS: OR, 0.96 [95% CI, 0.69–1.33]). These results were consistent with the secondary outcomes of ischemia-driven target lesion revascularization, target vessel myocardial infarction, and target vessel revascularization, and sensitivity analyses generally did not reveal inconsistency. OCT was associated with a significant reduction of stent thrombosis compared with ICA (OR, 0.49 [95% CI, 0.26–0.92]) but only in the frequentist analysis. Similarly, the results in terms of survival between IVUS or OCT and ICA were uncertain across analyses. A total of 25 randomized trials (17 128 patients) were included in the pairwise meta-analyses IVI versus ICA where IVI guidance was associated with reduced target lesion revascularization, cardiac death, and stent thrombosis. CONCLUSIONS: IVI-guided PCI was associated with a reduction in ischemia-driven target lesion revascularization compared with ICA-guided PCI, with the difference most evident for IVUS. In contrast, no significant differences in myocardial infarction were observed between guidance strategies.